# Biomedical Technologies and Innovation Doctoral Programme (BIOTIN)







| Title of the PhD<br>Project                              | Targeted drug delivery for oncology applications  |
|--|---|
| Acronym  | TADDO   |
| Research Fields<br>of the Project                        | Organic Chemistry, Polymer Chemistry, Molecular Biology, Pharmacy, Pharmaceutical Technology, Analytical Biotechnology.   |
| Keywords   | Nanomedicine, Drug Delivery, Polymer synthesis, Organic synthesis, Pharmaceutics, Cell biology  |
| Host Institution, Department and Campus Location         | Boğazici University, Department of Chemistry, North Campus, Bebek, Istanbul   |
| PhD Awarding<br>Institution and<br>Graduate<br>Programme | Boğazici University, Institute of Biomedical Engineering, PhD in Biomedical Engineering   |
| Name and<br>Affiliation of<br>Main Supervisor            | Prof. Rana Sanyal (BOUN)  |
| Name and<br>Affiliation of Co-<br>supervisors            | Prof. Cengizhan Ozturk (BOUN)  Prof. Esra Erdal (IBG)   |
| Research<br>Environment<br>and<br>Infrastructure         | Boğaziçi University one of the top public universities in Turkey. It has excellent research facilities to conduct cutting-edge projects. The researcher will have access to labs ( <a href="https://sanyalgroup.boun.edu.tr/">https://sanyalgroup.boun.edu.tr/</a> ) and instrumentation at the Center for Life Sciences and Technologies ( <a href="https://lifesci.boun.edu.tr/en">https://lifesci.boun.edu.tr/en</a> ), Institute of Biomedical Engineering ( <a href="https://bme.boun.edu.tr/">https://bme.boun.edu.tr/</a> ) and the Department of Chemistry ( <a href="https://www.chem.boun.edu.tr/">https://www.chem.boun.edu.tr/</a> ). |
| Scientific<br>Context of the<br>Project                  | Quality of life for cancer patients is drastically reduced due to deleterious side effects of chemotherapy. As the chemotherapy agents, which are the forefront tools to fight against cancer, are extensively toxic to the whole body, these conventional cancer treatment drugs attack cancer cells as well as healthy cells, leaving the patient vulnerable to other diseases.   |
|  | Our solution offer to this problem is to package the chemotherapy agent in a manner to protect the agent from the body and the body from the agent till it reaches its destination: the tumor. The packaging, grandiosely termed as the nanomedicine, will be referring to the polymer therapeutic, more precisely polymer-drug conjugate. Polymer therapeutics share many properties of the biologics (proteins, antibodies,   |

### Biomedical Technologies and Innovation Doctoral Programme (BIOTIN)







|                   | oligonucleotides) with a bonus of synthetic chemistry utilities: tailoring of molecular   |
|-------------------|---|
|                   | weight and addition of biomimetic and bioresponsive features to the man-made  |
|                   | construct. The successful polymer-drug conjugate has many advantages including  |
|                   | improved water solubility (physical properties) and pharmacokinetic properties (the   |
|                   | way the molecules behave in the body), better toxicity profile (reduced side effects),  |
|                   | less frequent administration in the clinic and a patent application as a new entity   |
|                   | patent, indulging the pharmaceutical industry.  |
|                   |   |
|                   | The sub projects of the thesis will gather around the theme of novel nanocarriers,  |
|                   | starting from the preparation and continuing on the evaluation of the nanomedicines   |
|                   | in vitro and in vivo. Our prior experience in developing nanomedicines from bench to  |
|                   | bedside via the start-up approach will enlighten our way in moving these academic   |
|                   | curiosities into high-impact solutions.   |
| Brief Workplan    | Synthesis of novel copolymers using controlled polymerization techniques,   |
|                   | preparation of nanoparticle formulations, attachment of antibody as a targeting   |
|                   | agent, purification and characterization of the nanomedicines, in vitro evaluation of   |
|                   | drug release and biological activity, in vivo evaluation in efficacy models.  |
| Innovative        | The nevel ty stems from the design of the nelumeric corriers and drug linker  |
| Aspects of the    | The novelty stems from the design of the polymeric carriers and drug-linker-polymer-antibody combinations. A modular synthetic approach to assemble the |
| •                 |   |
| Project           | targeted nanomedicines will enable novel entities with very high drug to antibody   |
|                   | ratios (DARs). The nanomedicines will be evaluated in vitro in 3D cell cultures (organoids).  |
|                   | (organious).  |
| Training          | The researcher will be trained in the area of polymer synthesis, nanoparticle   |
| Opportunities     | preparation, biomolecule conjugation technologies, biotechnological purification  |
| of the Project    | and characterization methods, drug delivery and in vitro biological evaluations.  |
|                   | There will be opportunity for participation of the researcher in <i>in vivo</i> evaluation.   |
|                   |   |
| Interdisciplinary | This highly multidisciplinary project involves organic chemistry, polymer chemistry,  |
| Aspects           | chemical biology (bioconjugation techniques), analytical biotechnology  |
|                   | (characterization and purification techniques), pharmaceutical technology   |
|                   | (preparation of nanomedicines and drug release), molecular biology (in vitro  |
|                   | evaluations).   |
| Intersectoral     | Host: RS Research   |
| Mobility          |   |
| -                 | Context of Mobility: Training in pharmaceutical formulation and analytical  |
| Short Visit       | biotechnology   |
| ☐ Secondment      |   |
| Intersectoral     | Host: Istanbul Health Industry Cluster (ISEK)   |
| Mobility          |   |
| -                 | Context of Mobility: Entrepreneurship Training, Thematic Pre-incubation Program   |
| ☑ Short Visit     |   |
| ☐ Secondment      |   |

## Biomedical Technologies and Innovation Doctoral Programme (BIOTIN)







| International |
|---------------|
| Academic      |
| Secondment    |

Host Supervisor: Prof. Carlo Catapano

Host Institution: Università della Svizzera italiana, Institute of Oncology Research,

Bellinzona, Switzerland

Host Department: Tumor Biology and Experimental Therapeutics program

Duration: 6 months

Estimated Time of Mobility: During the second half of PhD

### **Main Supervisor**

Brief CV Prof. Rana Sanyal

E-mail: rana.sanyal@boun.edu.tr

**ACADEMIC DEGREES** 

Ph.D. Chemistry Boston University, USA 2001
B.Sc. Chemical Engineering Boğaziçi University, Turkey 1994

Google Scholar: <a href="https://scholar.google.com/citations?hl=en&user=sFTumloAAAAJ">https://scholar.google.com/citations?hl=en&user=sFTumloAAAAJ</a>

https://orcid.org/0000-0003-4803-5811

#### **Co-supervisors**

Brief CV Prof. Cengizhan Öztürk

E-mail: cozturk@boun.edu.tr

**ACADEMIC DEGREES** 

Ph.D.Biomedical EngineeringDrexel University, USA1997Spec.PhysiologyIstanbul University, Cerrahpaşa Medical Faculty1994M.D.MedicineMarmara University, Turkey1990

Google Scholar: <a href="https://scholar.google.com/citations?user=IdHoVggAAAAJ&hl=tr&oi=ao">https://scholar.google.com/citations?user=IdHoVggAAAAJ&hl=tr&oi=ao</a> <a href="https://orcid.org/0000-0002-6966-0774">https://orcid.org/0000-0002-6966-0774</a>

Brief CV Prof. Esra Erdal

E-mail: esra.erdal@ibg.edu.tr

**ACADEMIC DEGREES** 

Ph.D. Molecular Biology and Genetics
 M.Sc. Biotechnology
 Bilkent University, Turkiye
 Middle East Technical University, Turkey
 Biology
 Middle East Technical University, Turkey
 1991

Google Scholar: <a href="https://scholar.google.com.tr/citations?user=d-T8dvAAAAAJ&hl=en">https://scholar.google.com.tr/citations?user=d-T8dvAAAAAJ&hl=en</a>

https://orcid.org/0000-0001-7264-0574